Cargando…
SRT2183 and SRT1720, but not Resveratrol, Inhibit Osteoclast Formation and Resorption in the Presence or Absence of Sirt1
BACKGROUND: Osteoclastic bone resorption markedly increases with aging, leading to osteoporosis characterized by weak and fragile bones. Mice exhibit greater bone resorption and poor bone mass when Sirt1 is removed from their osteoclasts. Here we investigated the ex vivo impacts of putative Sirt1 ac...
Autores principales: | Thiyagarajan, Ramkumar, Gonzalez, Maria Rodríguez, Zaw, Catherine, Seldeen, Kenneth Ladd, Hernandez, Mireya, Pang, Manhui, Troen, Bruce Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500633/ https://www.ncbi.nlm.nih.gov/pubmed/37711761 |
Ejemplares similares
-
SRT2183 impairs ovarian cancer by facilitating autophagy
por: Sun, Tingting, et al.
Publicado: (2020) -
The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells
por: Gurt, Irina, et al.
Publicado: (2015) -
SRT1720 improves survival and healthspan of obese mice
por: Minor, Robin K., et al.
Publicado: (2011) -
SRT1720 as an SIRT1 activator for alleviating paraquat-induced models of Parkinson's disease
por: Chao, Chih-Chang, et al.
Publicado: (2022) -
CORRIGENDUM: SRT1720 improves survival and healthspan of obese mice
por: Minor, Robin K., et al.
Publicado: (2013)